Navigation Links
Stem cells used to model disease that causes abnormal bone growth
Date:1/8/2014

Researchers have developed a new way to study bone disorders and bone growth, using stem cells from patients afflicted with a rare, genetic bone disease. The approach, based on Nobel-Prize winning techniques, could illuminate the illness, in which muscles and tendons progressively turn into bone, and addresses the similar destructive process that afflicts a growing number of veterans who have suffered blast injuries including traumatic amputations or injuries to the brain and nervous system. This insidious hardening of tissues also grips some patients following joint replacement or severe bone injuries.

The disease model, described in a new study by a UC San Francisco-led team, involves taking skin cells from patients with the bone disease, reprogramming them in a lab dish to their embryonic state, and deriving stem cells from them.

Once the team derived the stem cells, they identified a cellular mechanism that drives abnormal bone growth in the thus-far untreatable bone disease, called fibrodysplasia ossificans progressiva (FOP). Furthermore, they found that certain chemicals could slow abnormal bone growth in the stem cells, a discovery that might help guide future drug development.

Clinically, the genetic and trauma-caused conditions are very similar, with bone formation in muscle leading to pain and restricted movement, according to the leader of the new study, Edward Hsiao, MD, PhD, an endocrinologist who cares for patients with rare and unusual bone diseases at the UCSF Metabolic Bone Clinic in the Division of Endocrinology and Metabolism.

The human cell-based disease model is expected to lead to a better understanding of these disorders and other illnesses, Hsiao said.

"The new FOP model already has shed light on the disease process in FOP by showing that the mutated gene can affect different steps of bone formation," Hsiao said. "These different stages represent potential targets for limiting or stopping the
'/>"/>

Contact: Jeffrey Norris
jeffrey.norris@ucsf.edu
415-502-6397
University of California - San Francisco
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Tortoise and the hare: New drug stops rushing cancer cells, slow and steady healthy cells unharmed
2. Stem cells can repair a damaged cornea
3. Scientists produce eye structures from human blood-derived stem cells
4. Study demonstrates cells can acquire new functions through transcriptional regulatory network
5. Epigenetic signatures direct the repair potential of reprogrammed cells
6. Researchers print live cells with a standard inkjet printer
7. Nanopills release drugs directly from the inside of cells
8. Protein jailbreak helps breast cancer cells live
9. Newly found protein helps cells build tissues
10. BU researchers derive purified lung and thyroid progenitors from embryonic stem cells
11. Housekeeping mechanism for brain stem cells discovered
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ) has ... - NEC" report to their offering. ... to supply a range of IT security management and ... on the development of a Big Data and cloud ... Asia-Pacific region is a core ...
(Date:4/8/2015)... N.C. , April 8, 2015  Infinisource, ... solutions and services, and Morpho, a leading supplier ... partnership to produce the market,s most advanced biometrically-enabled ... Infinisource,s iSolved NXG time clock is setting a ... and labor data for the small and mid-size ...
(Date:4/2/2015)... HAMBURG, Germany , April 2, 2015 /PRNewswire/ ... ten fingerprint tests DERMALOG by far outperforms the ... While always maintaining high accuracy, the system is ... second. Hence, the speed proves up to be ... 40% faster than its runner-up performance. ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... in the brain may unlock the mystery behind the ... issue of Cell. Hibernation allows animals from bears to ... the harshest of winter conditions. , If the findings ... first essential brain signal governing the seasonal adaptation, according ...
... amino acid supplement L-arginine following a heart attack does ... be associated with an increased risk of death, according ... JAMA. , L-arginine is a widely available dietary supplement ... hypertension, angina, heart failure and sexual dysfunction, according to ...
... "biobullet" that could help control an invasive mollusk that ... water pipes, virtually wiping out some native mussels species ... new microcapsules, which contain toxins that dissolve within a ... way of eliminating one of the world's "most important ...
Cached Biology News:Possible brain hormone may unlock mystery of hibernation 2Possible brain hormone may unlock mystery of hibernation 3Use of amino acid supplement following a heart attack provides no benefit, may be harmful 2'Biobullets' fight harmful mussels 2
(Date:4/21/2015)... 2015 Staying true to their mission ... digital product that makes the world a better place, ... Standards Institute (GBSI) to redesign their website ( http://www.gbsi.org ... importantly, strategy-based. , "Biomedical research is not always an ... to promote it in a narrative way on a ...
(Date:4/21/2015)... YORK , April 21, 2015 AbilTo, ... today that its abstract submission has been accepted as ... Association,s (ADA) annual meeting taking place on June 5-6, 2015 ... According to the American Diabetes Association, the cost ... was $245 billion. As a result of increased inpatient, ...
(Date:4/21/2015)... 2015 Invetech , a global ... and contract manufacturing, and  NanoCellect Biomedical, a ... cell sorting technology for life science researchers, today ... cytometry platform. Headquartered in ... a microchip-based cell sorting technology. NanoCellect,s flow cytometry ...
(Date:4/21/2015)... 21, 2015 Immune Pharmaceuticals Inc., or "Immune" ... Directors has elected Rene-Pierre Azria as a ... Committee, with oversight on strategic and financial transactions. Mr. ... Committee, the Compensation Committee and the Corporate Governance and ... commented: "I have a long-time interest in Life Sciences ...
Breaking Biology Technology:Visceral Tells GBSI’s Story Within 30 Seconds of Attention 2Visceral Tells GBSI’s Story Within 30 Seconds of Attention 3AbilTo To Present at the 2015 American Diabetes Association Annual Meeting on Remote Delivery of Behavioral Change Therapy 2AbilTo To Present at the 2015 American Diabetes Association Annual Meeting on Remote Delivery of Behavioral Change Therapy 3NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 2NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 3Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 2Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 3Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 4
... , , MISSISSAUGA, ON, Nov. 23 /PRNewswire-FirstCall/ ... TSX: YM), a life sciences product development company that ... products at various stages of development, today reported that ... trial evaluating CYT387, a potent, orally-administered JAK1/JAK2 inhibitor. The ...
... , , SEATTLE, Nov. ... Bruce L.A. Carter has joined IDC as Executive Chairman. ... management. He was the former Chief Executive Officer at ... Nordisk, Copenhagen, Denmark. , (Photo: http://www.newscom.com/cgi-bin/prnh/20091123/SF15228 ) ...
... , REDWOOD CITY, Calif., Nov. ... therapeutic products for the treatment of chronic respiratory diseases, ... company,s Board of Directors. Mr. Rosen has 25 years ... key roles at Gilead Sciences and ALZA Corporation. His ...
Cached Biology Technology:YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 3YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 4YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 5Immune Design Corp. Announces Appointment of Dr. Bruce L.A. Carter as Executive Chairman and Director 2Pearl Therapeutics Appoints Howie Rosen to Board of Directors 2
...
...
...
... This antibody recognizes murine IRF7 ... with other related IRF proteins. ... murine IRF7 protein was confirmed ... the 293T cells transfected with ...
Biology Products: